medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Número 3

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2005; 52 (3)


Lípidos, aterogénesis y riesgo coronario

Barba EJR

Idioma: Español
Referencias bibliográficas: 55
Paginas: 138-151
Archivo PDF: 168.92 Kb.


RESUMEN

En las últimas tres décadas se ha involucrado los niveles altos de colesterol, particularmente en forma de colesterol LDL (C-LDL), como el factor de mayor riesgo de enfermedad coronaria. Sin embargo, investigaciones recientes han ampliado el conocimiento del metabolismo y función de las lipoproteínas, haciendo evidente que el C-LDL no es la única especie de lipoproteína involucrada en la aterogénesis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Walldius G, Jungnerl I. Apolipoprotein B and apolipoprotein A-1: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.

  2. Ramírez VC, Lozano NJJ, Rubio GAF. Nuevos conceptos fisiopatológicos y diagnósticos en los síndromes coronarios agudos. Med Int Mex 2004; 20: 437-450.

  3. Terrés-Speziale AM. El laboratorio clínico y la evaluación del riesgo coronario. Rev Mex Patol Clin 2000; 47 (4): 202-218.

  4. Gutiérrez RGM; Terrés-Speziale AM. Evaluación del riesgo aterogénico: Estudio comparativo de dos metodologías. Rev Mex Patol Clin 1993; 40 (2): 58-61.

  5. Sacco RL. Newer risk factors for stroke. Neurology 2001; 57 (5) (suppl 2): S31-S34.

  6. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104 (3): 365-372.

  7. Hutter CM, Austin MA, Humphries SE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: A HuGE Minireview. [Human Genome Epidemiology (HuGE) Review]. Am J Epidemiol 2004; 160 (5): 430-435.

  8. Muntner P, Coresh J, Smith J, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study [Clinical Nephrology-Epidemiology-Clinical Trials]. Kidney Internat 2000; 58 (1): 293-301.

  9. Pentikäinem MO, Öörni K, Ala-Korpela M, Kovanen PT. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Inter Med 2000; 247 (3): 359-370.

  10. Lamarche B, Techernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69-75.

  11. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldiusl G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-780.

  12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026-2033.

  13. Asztalos Bela F. High-density lipoprotein metabolism and progression of atherosclerosis: New insights from the HDL atherosclerosis treatment study [HDL cholesterol]. Cur Op Cardiol 2004; 19 (4): 385-391.

  14. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000; 102: 1886-1892.

  15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-2497.

  16. O’Connell BJ, Denise M, Genest J. Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation 2004; 110 (18): 2881-2888.

  17. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103 (9): 1194-1197.

  18. Eckel RH, Chair WM, Chair A, Sobel B, Barrett E, King G et al. Prevention conference VI: Diabetes and cardiovascular disease: Writing group II: Pathogenesis of atherosclerosis in diabetes. [AHA Conference Proceedings]. Circulation 2002; 105 (18): 38-43.

  19. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the wee-functioning elderly: Findings from the health, aging, and body composition study. Arteriosc Thromb Vasc Biol 2003; 23 (8): 1444-1448.

  20. Austin MA, Hutter CM, Zimmern RL, Humpries SE. Familial hypercholesterolemia and coronary heart disease: A HuGE association review. Am J Epidemiol 2004; 160 (5): 421-429.

  21. Jones SP, Girod WG, Marotti KR, Aw TY, Lefer DJ. Acute exposure to a high cholesterol diet attenuates myocardial ischemia-reperfusion injury in cholesteryl ester transfer protein mice. Cor Art Dis 2001; 12 (1): 37-44.

  22. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994; 120: 1012-1025.

  23. Durstine JL, Grandjean P, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopul Rehab 2002; 22 (6): 385-398.

  24. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels. Am J Cardiol 1991; 68: 187-192.

  25. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on troke prevention: A meta-analysis of randomized trials. Arch Inter Med 2003; 163 (6): 669-676.

  26. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-459.

  27. Lamarche B, Moorjani S, Lupien PJ et al. Apoliprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 1996; 94: 273-278.

  28. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-1460.

  29. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopul Rehab 2002; 22 (6): 385-398.

  30. Canal J. Primera Jornada del Internado en Farmacia de los Hospitales de París. Act Pharm Biol Clin 1981; 1: 29-37.

  31. Pantoni L, Sarti C, Pracucci G, Di Carlo A, Vanni P, Inzitari D. Lipoprotein(a) serum levels and vascular diseases in an older caucasian population cohort. J Am Geriatr Soc 2001; 49 (2): 117-125.

  32. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New Engl J Med 2003; 349 (22): 2108-2115.

  33. Kullo IJ, Bailey KR, Bielak LF, Sheedy PF, Klee GG, Kardia SL et al. Lack of association between lipoprotein(a) and coronary artery calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) Study. Mayo Clin Proceed 2004; 79 (10): 1258-1263.

  34. Uchida T, Inoue T, Kamishirado H, Takayanagi K, Morooka S. Prediction of short-term progression or regression of atherosclerotic coronary artery disease by lipoprotein(a): A quantitative coronary angiographic study. Angiology 2003; 54 (6): 641-646.

  35. Scharrett AR, Ballantyne CM, Coady SA, HeissG, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-1113.

  36. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001; 88: 265-269.

  37. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2571-2522.

  38. Radunovic N, Kuczynski E, Rosen T, Dukanac J, Petkovic S, Lockwood CJ. Plasma apolipoprotein A-I and B concentrations in growth-retarded fetuses: A link between low birth weight and adult atherosclerosis. J Clin Endocrinol Metabol 2000; 85 (1): 85-88.

  39. Sniderman AD, Pedersen T, Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997; 79: 64-67.

  40. Shah Prediman K et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming (Part II). Circulation 2001; 104 (20): 2498-2502.

  41. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-1460.

  42. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arteriosc Thromb Vasc Biol 2004; 24 (3): 421-428.

  43. Wang X, Pease R, Bertinato J, Milne R. Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism. Arteriosc Thromb Vasc Biol 2000; 20 (5): 1301-1308.

  44. Pietzsch J, Bergmann R. Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of metal catalyzed oxidation of praline and arginine residues of low density lipoprotein apolipoprotein B-100 in human atherosclerotic lesions. J Clin Pathol 2003; 56 (8): 622-623.

  45. Chen Z, Fitzgerald RL, Saffitz JE, Semenkovich CF, Schonfeld G. Amino terminal 38.9% of apolipoprotein B-100 is sufficient to support cholesterol-rich lipoprotein production and atherosclerosis. Arteriosc Thromb Vasc Biol 2003; 23 (4): 668-674.

  46. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time: In vivo insights from stable-isotope studies. Arteriosc Thromb Vasc Biol 2000; 20 (10): e63-e67.

  47. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002; 90 (suppl): 22i-29i.

  48. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106 (20): 2526-2529.

  49. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363-366.

  50. Watts GF, Herrmann S, Riches FM. Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. Oxford University Press 2000; 93 (3): 153-161.

  51. Mooser V, Helbecque N, Miklossy J, Marcovina SM, Nicod P, Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. Ann Inter Med 2000; 132 (7): 533-537.

  52. Boden WE. Recent insights into the expanding role of high-density lipoprotein cholesterol in dyslipidemia and disease. Curr Op Cardiol 2004; 19 (4): 363-365.

  53. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003; 34 (3): 623-631.

  54. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996; 94: 2351-2354.

  55. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of stains on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326: 1423-1427.




2020     |     www.medigraphic.com